MDxHealth SA (NASDAQ:MDXH) Short Interest Update

MDxHealth SA (NASDAQ:MDXH) saw a significant drop in short interest in the month of June. As of June 15th, there was short interest totaling 106,013 shares, a drop of 76.8% from the May 31st total of 457,830 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 796,277 shares, the short-interest ratio is currently 0.1 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE raised its stake in shares of MDxHealth by 213.9% during the first quarter. Bank of America Corp DE now owns 43,492 shares of the company’s stock worth $100,000 after acquiring an additional 29,638 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of MDxHealth by 21.8% in the 1st quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock valued at $701,000 after purchasing an additional 54,600 shares in the last quarter. Perkins Capital Management Inc. grew its holdings in shares of MDxHealth by 7.1% during the 1st quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock valued at $3,396,000 after purchasing an additional 97,500 shares during the last quarter. XTX Topco Ltd grew its holdings in shares of MDxHealth by 220.0% during the 4th quarter. XTX Topco Ltd now owns 40,860 shares of the company’s stock valued at $146,000 after purchasing an additional 28,090 shares during the last quarter. Finally, Millennium Management LLC raised its position in MDxHealth by 328.3% in the 4th quarter. Millennium Management LLC now owns 116,831 shares of the company’s stock worth $417,000 after purchasing an additional 89,553 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on MDXH. BTIG Research decreased their target price on MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a report on Friday, March 27th. William Blair cut shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. TD Cowen reaffirmed a “buy” rating and issued a $1.50 target price (down from $7.00) on shares of MDxHealth in a research note on Thursday, May 14th. Finally, Wall Street Zen lowered shares of MDxHealth from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $4.62.

MDxHealth Trading Down 6.3%

NASDAQ MDXH traded down $0.03 during trading hours on Monday, reaching $0.40. 1,243,530 shares of the stock traded hands, compared to its average volume of 792,130. The stock has a 50 day simple moving average of $1.13 and a two-hundred day simple moving average of $2.49. MDxHealth has a 1 year low of $0.40 and a 1 year high of $5.33.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The firm had revenue of $23.90 million during the quarter, compared to analysts’ expectations of $30.89 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 29.90%. Research analysts forecast that MDxHealth will post -0.6 EPS for the current fiscal year.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.